Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Mersana Therapeutics appoints Mohan Bala as SVP, strategic product planning » 08:17
10/25/21
10/25
08:17
10/25/21
08:17
MRSN

Mersana Therapeutics

$8.49 /

+0.12 (+1.43%)

, CNST

Constellation Pharmaceuticals

$33.99 /

+ (+0.00%)

Mersana Therapeutics…

Mersana Therapeutics (MRSN) announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and CFO. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's principal financial officer. Mohan Bala, Ph.D., was most recently Chief Operating Officer at Constellation Pharmaceuticals (CNST).

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.49 /

+0.12 (+1.43%)

CNST Constellation Pharmaceuticals
$33.99 /

+ (+0.00%)

MRSN Mersana Therapeutics
$8.49 /

+0.12 (+1.43%)

10/14/21 BTIG
Mersana Therapeutics assumed with a Buy at BTIG
08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
CNST Constellation Pharmaceuticals
$33.99 /

+ (+0.00%)

07/27/21 SVB Leerink
MorphoSys price target lowered to EUR 96 from EUR 106 at SVB Leerink
06/17/21 RBC Capital
Constellation Pharma cut to Sector Perform from Outperform at RBC Capital
06/03/21 Jefferies
Constellation Pharmaceuticals downgraded to Hold from Buy at Jefferies
06/03/21 Truist
Constellation Pharmaceuticals downgraded to Hold from Buy at Truist
MRSN Mersana Therapeutics
$8.49 /

+0.12 (+1.43%)

CNST Constellation Pharmaceuticals
$33.99 /

+ (+0.00%)

CNST Constellation Pharmaceuticals
$33.99 /

+ (+0.00%)

CNST Constellation Pharmaceuticals
$33.99 /

+ (+0.00%)

Over a week ago
Conference/Events
Mersana Therapeutics participates in a conference call with JPMorgan » 10:25
10/20/21
10/20
10:25
10/20/21
10:25
MRSN

Mersana Therapeutics

$8.55 /

-0.24 (-2.73%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Protopapas on October 20 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.55 /

-0.24 (-2.73%)

MRSN Mersana Therapeutics
$8.55 /

-0.24 (-2.73%)

10/14/21 BTIG
Mersana Therapeutics assumed with a Buy at BTIG
08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
MRSN Mersana Therapeutics
$8.55 /

-0.24 (-2.73%)

Conference/Events
Mersana Therapeutics participates in a conference call with JPMorgan » 04:55
10/20/21
10/20
04:55
10/20/21
04:55
MRSN

Mersana Therapeutics

$8.79 /

+0.43 (+5.14%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Protopapas on October 20 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.79 /

+0.43 (+5.14%)

MRSN Mersana Therapeutics
$8.79 /

+0.43 (+5.14%)

10/14/21 BTIG
Mersana Therapeutics assumed with a Buy at BTIG
08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
MRSN Mersana Therapeutics
$8.79 /

+0.43 (+5.14%)

Conference/Events
Mersana Therapeutics participates in a conference call with JPMorgan » 15:59
10/19/21
10/19
15:59
10/19/21
15:59
MRSN

Mersana Therapeutics

$8.78 /

+0.42 (+5.02%)

SMid Cap Biotech Analyst…

SMid Cap Biotech Analyst Fye holds a conference call with CEO Protopapas on October 20 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.78 /

+0.42 (+5.02%)

MRSN Mersana Therapeutics
$8.78 /

+0.42 (+5.02%)

10/14/21 BTIG
Mersana Therapeutics assumed with a Buy at BTIG
08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
MRSN Mersana Therapeutics
$8.78 /

+0.42 (+5.02%)

Initiation
Mersana Therapeutics assumed with a Buy at BTIG » 16:28
10/14/21
10/14
16:28
10/14/21
16:28
MRSN

Mersana Therapeutics

$8.47 /

-0.19 (-2.19%)

BTIG analyst Kaveri…

BTIG analyst Kaveri Pohlman assumed coverage of Mersana Therapeutics with a Buy rating and $32 price target. The analyst assumed coverage of 12 Immuno-oncology companies. Pohlman believes "much of the most promising work" involves broader immune involvement in the anti-tumor battle either involving or in combination with less-systemically toxic therapeutic cytokines. The world of allogeneic cellular therapies is "very close to catching the autologous world but that these approaches will always be complex for smaller hospitals to employ leaving this approach for a subset of patients," Pohlman tells investors in a research note.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.47 /

-0.19 (-2.19%)

MRSN Mersana Therapeutics
$8.47 /

-0.19 (-2.19%)

08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
MRSN Mersana Therapeutics
$8.47 /

-0.19 (-2.19%)

Conference/Events
Mersana Therapeutics participates in a conference call with Wedbush » 12:25
10/11/21
10/11
12:25
10/11/21
12:25
MRSN

Mersana Therapeutics

$9.09 /

+0.225 (+2.54%)

Wedbush Biotechnology…

Wedbush Biotechnology Analyst Nierengarten holds a conference call with President & CEO Protopapas and SVP DeSchuuytner on October 11 at 1 pm hosted by Wedbush.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$9.09 /

+0.225 (+2.54%)

MRSN Mersana Therapeutics
$9.09 /

+0.225 (+2.54%)

08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
MRSN Mersana Therapeutics
$9.09 /

+0.225 (+2.54%)

Conference/Events
Mersana Therapeutics participates in a conference call with Wedbush » 04:55
10/11/21
10/11
04:55
10/11/21
04:55
MRSN

Mersana Therapeutics

$8.84 /

-0.16 (-1.78%)

Wedbush Biotechnology…

Wedbush Biotechnology Analyst Nierengarten holds a conference call with President & CEO Protopapas and SVP DeSchuuytner on October 11 at 1 pm hosted by Wedbush.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.84 /

-0.16 (-1.78%)

MRSN Mersana Therapeutics
$8.84 /

-0.16 (-1.78%)

08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
MRSN Mersana Therapeutics
$8.84 /

-0.16 (-1.78%)

Conference/Events
Mersana Therapeutics participates in a conference call with Wedbush » 10:49
10/08/21
10/08
10:49
10/08/21
10:49
MRSN

Mersana Therapeutics

$9.12 /

+0.12 (+1.33%)

Wedbush Biotechnology…

Wedbush Biotechnology Analyst Nierengarten holds a conference call with President & CEO Protopapas and SVP DeSchuuytner on October 11 at 1 pm hosted by Wedbush.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$9.12 /

+0.12 (+1.33%)

MRSN Mersana Therapeutics
$9.12 /

+0.12 (+1.33%)

08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
MRSN Mersana Therapeutics
$9.12 /

+0.12 (+1.33%)

Hot Stocks
Mersana Therapeutics presents new XMT-2056 data at AACR-NCI-EORTC conference » 16:08
10/07/21
10/07
16:08
10/07/21
16:08
MRSN

Mersana Therapeutics

$8.94 /

+ (+0.00%)

Mersana Therapeutics…

Mersana Therapeutics announced that XMT-2056, its first Immunosynthen STING-agonist ADC candidate, targets a novel epitope of human epidermal growth factor receptor 2, or HER2, and presented new preclinical data during a plenary session at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. New preclinical data presented at the Triple Meeting include: XMT-2056 demonstrated increased efficacy in both high and low HER2 SCID mouse models in comparison to benchmark agents such as a trastuzumab-TLR7/8 agonist ADC as well as a small molecule systemically-administered STING agonist. XMT-2056 showed excellent in vivo efficacy as a single agent in a SKOV3 HER2 high model and this efficacy is further enhanced by combining XMT-2056 with a 3 mg/kg dose of trastuzumab. XMT-2056 was generally well-tolerated in NHP studies with no clinical signs and no adverse findings in clinical pathology or histopathology after single and repeat IV doses of 9 mg/kg, at exposures far exceeding those necessary for efficacy in mouse models, indicating the potential for a wide therapeutic index.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$8.94 /

+ (+0.00%)

MRSN Mersana Therapeutics
$8.94 /

+ (+0.00%)

08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
MRSN Mersana Therapeutics
$8.94 /

+ (+0.00%)

Hot Stocks
Mersana to announce target, present XMT-2056 data at AACR-NCI-EORTC conference » 08:05
09/30/21
09/30
08:05
09/30/21
08:05
MRSN

Mersana Therapeutics

$9.33 /

-0.16 (-1.69%)

Mersana Therapeutics…

Mersana Therapeutics announced that it will disclose the target and present new preclinical data for XMT-2056, its first Immunosynthen STING-agonist ADC candidate, in a plenary session at the upcoming AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.

ShowHide Related Items >><<
MRSN Mersana Therapeutics
$9.33 /

-0.16 (-1.69%)

MRSN Mersana Therapeutics
$9.33 /

-0.16 (-1.69%)

08/30/21 H.C. Wainwright
Mersana Therapeutics initiated with a Buy at H.C. Wainwright
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Mersana Therapeutics initiated with a Neutral at Credit Suisse
12/02/20 Stifel
Mersana Therapeutics initiated with a Buy at Stifel
MRSN Mersana Therapeutics
$9.33 /

-0.16 (-1.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.